Premium
The clinical conundrum of managing 5‐fluorouracil–induced vasospasm in colorectal carcinoma
Author(s) -
Nohria Anju
Publication year - 2019
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32486
Subject(s) - cardiotoxicity , medicine , fluorouracil , limiting , coronary vasospasm , colorectal cancer , adverse effect , vasospasm , oncology , toxicity , cardiology , chemotherapy , cancer , subarachnoid hemorrhage , myocardial infarction , mechanical engineering , coronary angiography , engineering
Fluoropyrimidine‐associated cardiotoxicity can be a therapy‐limiting adverse effect that largely depends on the mode of fluoropyrimidine administration. We discuss strategies for re‐challenge after incident cardiotoxicity that can reduce, but not eliminate, the risk of recurrent cardiotoxicity.